Company: KROS
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-037982
Chunk: 43

Company: Keros Therapeutics, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 43
---
 that are exercisable within 60 days of April 11, 2025. OPI VII and Genesis are collectively referred to as the OrbiMed Entities. OrbiMed GP VII is the general partner of OPI VII. OrbiMed Advisors is the managing member of OrbiMed GP VII. By virtue of such relationships, OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and as a result may be deemed to have beneficial ownership over such securities. Genesis GP is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by the OrbiMed Entities. Carl L. Gordon, Ph.D., C.F.A., a member of OrbiMed Advisors, is a member of our Board. The business address of each of the OrbiMed Entities is c/o OrbiMed Advisors LLC, 601 Lexington Avenue, 54th Floor, New York, NY 10022. (11) Consists of shares issuable upon the exercise of options granted to Dr. Gray that are exercisable within 60 days of April 11, 2025. (12) Includes 36,586 shares issuable upon the exercise of options granted to Mr. Kariv that are exercisable within 60 days of April 11, 2025. (13) Consists of (i) 341,574 shares of common stock held by Partners Innovation Fund, LLC (“ PIF I ”), (ii) 232,727 shares of common stock held by Partners Innovation Fund II, L.P. (“ PIF II ”), (iii) 1,191 shares of common stock held by Mr. Knowles and (iv) 36,586 shares issuable upon the exercise of options granted to Mr. Knowles that are exercisable within 60 days of April 11, 2025. PIF I and PIF II are collectively referred to as the “Partners Entities.” Partners Innovation